The excellent performance of our miRNA panel, compared with AFP as the only clinically-accepted biomarker in HCC, also suggests that we may not be too far away from a validated diagnostic HCC miRNA panel that could be used in clinical practice. This evidence concerns the gene AFP and hepatocellular carcinoma.